Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Tumor ; (12): 145-151, 2018.
Article in Chinese | WPRIM | ID: wpr-848425

ABSTRACT

Carrying nucleic acids, proteins, lipids and other substances, the tumor microenvironment-derived and cancer-derived exosomes promote tumor metastasis through intercellular communication. These exosomes mediate epithelial-mesenchymal transition (EMT) of tumor cells, which is a key step in tumor invasion and distant metastasis. Exosomes also play important roles in creating tumor microenvironment to help tumor cells escape immune surveillance and to promote the formation of pre-metastatic niche for the engraftment of detached cancer cells. In this review, the progress in multifaceted roles of exosomes in tumor metastasis by inducing EMT, regulating immune response and promoting the formation of pre-metastatic microenvironment was discussed.

2.
Chinese Journal of Immunology ; (12): 90-92, 2015.
Article in Chinese | WPRIM | ID: wpr-459687

ABSTRACT

Objective:To study feasibility of preparing artificial antigen by membrane coated with hapten-carrier.To compare the Emodin-BSA membrane antigen immunogenicity and specificity against the liquid antigen.Methods:Emodin-BSA-PVDF membrane was prepared by the method that BSA was coated on PVDF membrane and the BSA was coupled with Emodin-couplint agent derivative.Rats were immunized by subcutaneous implantation.The immunogenicity and antibody specificity were characterized using Emodin-CA or Chrysophanol-CA or Physcion-CA membrane immunoassay. Results: The immunogenicity of Emodin-BSA coated membrane antigen was higher than Emodin-BSA liquid antigen;the specificity for three anthraquinones was almost the same(P>0.05). Conclusion:Emodin antiserum generated using Emodin-BSA coated membrane antigen has a high immunogenicity and specificity to Emodin.The results show it is feasible that membrane coated with hapten-carrier is used as artificial antigen.

3.
Chinese Journal of Urology ; (12): 12-14, 2010.
Article in Chinese | WPRIM | ID: wpr-391375

ABSTRACT

Objective To evaluate the tolerance and safety of sorafenib for elderly patients with advanced renal cell carcinoma.Methods Forty cases with advanced renal cell carcinoma were enrolled,26 were males and 14 were females,the average age was 70 years.Recurrence or metastasis was found in 32 patients who had received nephrectomy,22 of the 32 cases had received cytokine therapy before recurrence or metastasis.Primary renal lesions of 8 cases could not be resected,so patients get renal tumor biopsy.Pathological type of all patients was clear cell carcinoma.KPS of all the patients were ≥70 points.Sorafenib was used as first-line treatment,with 400 mg twice per day,until intolerance or disease progression occurred.Results The average treatment time was 7.5 months (3-18 months),CR 0 case,PR 6 cases,SD 29 cases,PD 5 cases.The overall objective response rate and disease control rate were 15.0% (6/40)and 87.5%(35/40),respectively.The median follow-up period was 11 months.The adverse reaction included hand-foot skin reaction(70.0%),alopecia (62.5%),rash(52.5%),diarrhea(37.5%),loss of appetite(32.5%),fatigue(27.5%).Most adverse reactions occurred around the second week after drug therapy initiation,their duration did not equal.And most of these adverse reactions could be released by symptomatic treatment,they did not affect the treatment.Conclusions The types of adverse reactions of sorafenib for elderly patients with advanced renal cell carcinoma are similar to those reported in the literature.Generally the degree of adverse reactions is minor,with good tolerance and safety.

SELECTION OF CITATIONS
SEARCH DETAIL